Arumugham Raghunathan,
Sr. Director, Business Development, North America ,
Horizon Discovery Ltd
Currently Head of Business Development – Genome Editing Technology and Cell line Engineering at Horizon Discovery since January this year.
Sr. BD Executive role for Genome editing technologies and Biomarker/Target Discovery, ID, Validation Services and Personalized Medicine in the past year and half.
Field Application Scientist for RNAi, ZFN technology products and services at Sigma Aldrich for about 6 years
Sales Development/Management for Functional Genomics and Whole Genome amplification technologies for ~3 yrs with Qiagen
Co-inventor of a ‘Whole Genome Amplification’ technology at Molecular Staging Inc. Around 15 publications.
Scientist and R&D Group Leader in assay & method development, validation, product development and documentation at Molecular Staging Inc in for 4 yrs.
Postdoc at Yale School of Medicine, with Prof Sherman Weissman, department of genetics
Ph.D in Neuroscience from Univ of Hyderabad, India
|
|
|
Add to Calendar ▼2014-09-23 11:30:002014-09-23 12:30:00Europe/LondonGenome Editing as an Emerging Technology to Functionalize the Human Genome and Accelerate Targeted Drug DiscoveryAcademic Discovery Workshop in Baltimore, MD, USABaltimore, MD, USASELECTBIOenquiries@selectbiosciences.com
